Healthcare [ 5/11 ] | Biotechnology [ 72/148 ]
DE | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 10, 23 | 0.21 Increased by +195.45% | 0.21 |
| May 11, 23 | -0.21 Increased by +12.50% | -0.22 Increased by +4.55% |
| Mar 29, 23 | -0.63 Decreased by -162.50% | -0.24 Decreased by -162.50% |
| Mar 24, 23 | -0.28 Increased by +54.84% | -0.23 Decreased by -21.74% |
| Nov 10, 22 | -0.22 Decreased by -4.76% | -0.23 Increased by +4.35% |
| Aug 15, 22 | -0.24 Increased by +35.14% | -0.23 Decreased by -4.35% |
| May 16, 22 | -0.24 | -0.24 |
| Mar 30, 22 | -0.62 | -0.23 Decreased by -169.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 172.00 K Increased by +1.18% | -33.04 M Decreased by -7.08% | Decreased by -19.21 K% Decreased by -5.84% |
| Mar 31, 23 | 37.00 K Increased by +N/A% | -33.32 M Decreased by -4.25% | Decreased by -90.06 K% Decreased by N/A% |
| Dec 31, 22 | 38.00 K Increased by +N/A% | -45.32 M Increased by +13.07% | Decreased by -119.27 K% Decreased by N/A% |
| Sep 30, 22 | 24.00 K Decreased by -90.98% | -33.27 M Decreased by -6.78% | Decreased by -138.62 K% Decreased by -1.08 K% |
| Jun 30, 22 | 170.00 K Increased by +N/A% | -30.86 M Increased by +36.33% | Decreased by -18.15 K% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by -100.00% | -31.96 M Decreased by -4.75 K% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -52.14 M Increased by +39.79% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 266.00 K Increased by +N/A% | -31.16 M Increased by +62.55% | Decreased by -11.71 K% Decreased by N/A% |
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.